Volume 4, Issue 5, May 2026 ISSN (E): 2938-3765

EFFECTIVE MONITORING, TREATMENT AND PREVENTION OF ANEMIA CONCURRENT WITH HEART FAILURE IN THE CONDITIONS OF THE FERGANA VALLEY

Axunbayev Otabek Adilovich
Assistant of Fergana Medical Institute of Public Health

Abstract
This article provides a comprehensive analysis of the pathogenetic mechanisms, epidemiological burden, diagnostic approaches, and evidence-based treatment strategies for anemia coexisting with heart failure, with special emphasis on the clinical context of the Fergana Valley region. The cardiorenal anemia syndrome, hepcidin-mediated iron sequestration, erythropoietin resistance, and chronic neurohormonal activation are identified as the principal pathogenetic drivers worsening both conditions synergistically.

Keywords: heart failure, iron deficiency anemia, cardiorenal syndrome, hepcidin, ferric carboxymaltose, erythropoietin, transferrin saturation, ejection fraction, AFFIRM-AHF, neurohormonal activation, intravenous iron, hemoglobin, ferritin, NYHA classification, Central Asia cardiovascular burden

Introduction

Heart failure (HF) and anemia represent two of the most prevalent and clinically interrelated conditions encountered in internal medicine and cardiology. Globally, HF affects an estimated 64.3 million individuals, and anemia is found in 30 to 50 percent of this population, with prevalence rising sharply as functional class deteriorates. Uzbekistan registers more than 1.5 million acute and chronic cardiovascular disease cases annually, with newly diagnosed cases exceeding half a million each year, and over the past decade the primary incidence rate has increased 1.4 times. Cardiovascular disease incidence and prevalence in Central Asia show increasing trends in both urban and rural areas, with consistently high mortality rates, and key modifiable risk factors including hypertension, obesity, dyslipidemia, and smoking remain prevalent, particularly in rural settings. The Fergana Valley, as one of the most densely populated regions in Central Asia with historically limited specialist cardiology infrastructure, faces a disproportionate burden of this dual pathology. Iron deficiency is a common comorbidity in heart failure, affecting nearly 50 percent of patients and worsening symptoms, exercise capacity, and prognosis. Understanding this intersection - from its molecular underpinnings to its regional epidemiological context - is therefore both scientifically urgent and practically indispensable for clinicians in the Fergana Valley and across Uzbekistan.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Literature Review

The foundational framework for understanding anemia in heart failure was established through several landmark contributions. Horwich et al. (2002) published one of the first large registry-based analyses demonstrating that anemia is independently associated with significantly worse symptoms, greater functional impairment, and increased mortality in patients with advanced heart failure. Anker S.D. and Comin Colet J. (2009) conducted pivotal work showing that iron deficiency - even in the absence of anemia - independently predicts exercise intolerance and adverse outcomes in HF patients, fundamentally reframing iron deficiency as a primary therapeutic target rather than a mere laboratory finding. The FAIR-HF trial (Anker et al., 2009) and subsequently the CONFIRM-HF and AFFIRM-AHF trials demonstrated that intravenous ferric carboxymaltose significantly improves quality of life, exercise capacity, and reduces HF hospitalization rates. Ponikowski P. and colleagues (2023 ESC Guidelines update) formalized intravenous iron supplementation as a Class I recommendation for symptomatic iron-deficient patients with HFrEF. Rizzo C. and Passantino A. (2021) provided a comprehensive review consolidating the clinical evidence for ID treatment in HF. Tkaczyszyn M. et al. (2023) further evaluated whether further randomized trials are needed and analyzed individual patient data from multiple trials confirming the benefit of intravenous iron across a broad spectrum of HFrEF patients.

Main Body

The relationship between anemia and heart failure is not unidirectional but bidirectional and self-reinforcing - a vicious cycle in which each condition accelerates the other's progression through distinct yet interlocking mechanisms. Reduced cardiac output and erythropoietin insufficiency. In heart failure with reduced ejection fraction (HFrEF), diminished cardiac output reduces renal perfusion. The peritubular fibroblasts of the renal cortex, responsible for synthesizing approximately 90 percent of circulating erythropoietin (EPO), respond to this relative hypoxia by increasing EPO secretion. However, renal blood flow in CHF is relatively maintained until the late stages of the syndrome, especially when receiving angiotensin-converting enzyme inhibition, and EPO production does not seem to correlate with effective renal plasma flow. As heart failure advances, this compensatory mechanism fails, and EPO production becomes insufficient to sustain normal erythropoiesis. Hepcidin-mediated iron sequestration. Chronic heart failure is a state of persistent low-grade systemic inflammation. IL-6 activates the synthesis of the acute phase protein hepcidin in the liver, which is involved in the downregulation of ferroportin, decreasing duodenal iron absorption and the release of iron from its stores in the reticuloendothelial system, giving rise to functional and absolute iron deficiency anemia. This mechanism is of particular relevance in the Fergana Valley population, where nutritional iron adequacy may already be suboptimal in certain demographic groups, making hepcidin-driven iron sequestration a compounding pathogenetic layer. Neurohormonal activation and the cardiorenal anemia triangle. The pathologic triangle formed by chronic heart failure, chronic kidney disease, and anemia carries high morbidity and mortality rates and decreases quality of life, with total prevalence in cardiorenal syndrome ranging from 5 to 55 percent. Data from a population of more than one million patients show a two-year mortality risk that increased from 27 percent in patients with heart failure alone, to 35 percent in those with heart failure and anemia, 38 percent in those with both chronic kidney disease and heart failure, and 46 percent in

the cardiorenal anemia syndrome. These figures underscore the additive and synergistic lethality of this triad. Renin-angiotensin-aldosterone system (RAAS) inhibitors - cornerstone agents in HF therapy - paradoxically contribute to anemia by suppressing EPO synthesis and reducing red blood cell production, creating a pharmacological tension that clinicians must navigate carefully. Cytokine-mediated EPO resistance. Elevated levels of TNF-alpha, IL-6, and IL-1 found in heart failure patients are linked with poorer prognosis and outcomes, and these cytokines inhibit erythropoietin-stimulating agent-dependent erythropoietic processes in the bone marrow, causing EPO resistance, while also inhibiting iron remobilization through hepcidin production and decreasing endogenous EPO production in the kidney. This means that even when EPO levels are elevated, the bone marrow may respond inadequately - explaining why hemoglobin may fall despite rising EPO.

Accurate diagnosis of anemia in the context of heart failure requires a layered approach that distinguishes between absolute iron deficiency, functional iron deficiency, and anemia of chronic disease - three overlapping but pathophysiologically distinct entities.

The 2023 European Society of Cardiology guidelines define iron deficiency in HF as either absolute deficiency (serum ferritin < 100 µg/L) or functional deficiency (ferritin 100-299 µg/L with transferrin saturation below 20 percent). Current diagnostic criteria for ID in HF include absolute deficiency with ferritin below 100 µg/L and functional deficiency with ferritin 100-299 µg/L and transferrin saturation below 20 percent. Relying on hemoglobin alone is insufficient: iron deficiency remains under-recognised and under-treated in clinical practice, likely due in part to a lack of practical guidance for clinicians. In the Fergana Valley setting, where laboratory infrastructure may be variable across district hospitals and rural health facilities, a practical minimum diagnostic panel should include: complete blood count with reticulocyte index; serum ferritin and transferrin saturation (TSAT); serum creatinine and estimated GFR to assess renal contribution; and BNP or NT-proBNP to stratify HF severity. Echocardiography for ejection fraction measurement, where available, directly informs therapeutic decision-making, since treatment efficacy data from major trials predominantly relate to HFrEF (EF 40%).

Intravenous iron as the primary therapeutic modality. While oral iron therapy has limited efficacy, intravenous iron, particularly ferric carboxymaltose and ferric derisomaltose, improves symptoms and exercise tolerance and reduces hospitalizations, and intravenous iron is the preferred therapeutic approach. The mechanistic rationale is clear: intestinal congestion in heart failure impairs oral iron absorption, while chronic inflammation and elevated hepcidin further block enteral iron uptake. Intravenous delivery bypasses all of these barriers. A Bayesian meta-analysis combining individual patient data from FAIR-HF, CONFIRM-HF, and AFFIRM-AHF trials with IRONMAN results, totaling more than 3,000 patients, demonstrated that in a broad range of HFrEF patients with iron deficiency, treatment with intravenous iron reduced the composite of HF hospitalization or cardiovascular death. This constitutes the highest level of evidence for any intervention targeting anemia in heart failure. Erythropoiesis-stimulating agents: a cautionary note. Despite their theoretical rationale, erythropoiesis-stimulating agents (ESAs) have not demonstrated clinical benefit in randomized HF trials and have been associated with increased thrombotic risk. Treatment of anemia in patients with heart failure with erythropoiesis-stimulating agents has been evaluated intensively, but these agents did not improve outcomes and were associated with a higher risk of adverse events. In the cardiorenal anemia syndrome specifically, EPO resistance driven by inflammation limits their

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

effectiveness, and ESA use outside of concurrent CKD context is not currently guideline-endorsed for HF patients.

Emerging therapies. New therapeutic agents such as hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PH inhibitors) and hepcidin antagonists are emerging as potential tools for anemia therapy in the cardiorenal population. These agents work by stimulating endogenous EPO production or directly blocking hepcidin to restore iron availability. While clinical data in HF-specific populations remain limited, early results are promising and may redefine management in the coming decade.

Results

The synthesis of available evidence and regional epidemiological data yields the following key findings relevant to practice in the Fergana Valley.

Prevalence and severity correlation. Anemia prevalence in heart failure increases proportionally with NYHA functional class deterioration. In NYHA Class II patients, anemia is present in approximately 25-30 percent; this rises to over 50 percent in NYHA Class IV. Given that Uzbekistan's cardiovascular disease burden is increasing and that late-stage presentation is common in settings with limited primary care screening, a substantial proportion of HF patients in the Fergana Valley likely harbor undiagnosed iron deficiency or anemia. Prognostic impact is independent and substantial. Anemia is not merely a marker of advanced disease but an independent predictor of outcomes. Patients with HF and concurrent anemia demonstrate reduced six-minute walk distance, higher rates of re-hospitalization, and significantly elevated two-year mortality compared to non-anemic HF patients - all of which translate directly into greater healthcare burden in a resource-limited regional setting. Oral vs. intravenous iron: a practical regional decision. In district hospitals and polyclinics across the Fergana Valley, oral iron preparations are widely available, while intravenous iron formulations may require specialist referral. However, the evidence strongly favors intravenous iron for patients with confirmed ID and NYHA Class II-III symptoms. There are three main goals when treating patients with HFrEF: lessening mortality, preventing recurrent hospitalizations due to HF worsening, and improving functional capacity, clinical status, and quality of life - and intravenous iron directly addresses all three. Regional health systems should therefore prioritize reliable access to ferric carboxymaltose at cardiology centers. Diagnostic gaps, in regional clinical settings, transferrin saturation testing is not routinely performed alongside ferritin measurement. This gap means that functional iron deficiency - which may be the predominant form in HF patients with chronic inflammation - is systematically underdiagnosed. Implementing the dual ferritin/TSAT screening criterion as a standard protocol in all HF outpatient follow-up visits is the single most impactful diagnostic improvement available at low cost.

Discussion

The management of anemia in patients with heart failure in the Fergana Valley represents a clinical challenge at the intersection of epidemiology, pathophysiology, and healthcare infrastructure. Three key themes emerge from this analysis that are directly relevant to regional clinical practice. First, the paradigm shift from "treating hemoglobin" to "treating iron" represents the most important conceptual advance of the past decade. The evidence from major trials consistently shows that correcting iron

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

deficiency - irrespective of whether frank anemia is present - improves exercise capacity, reduces hospitalizations, and enhances quality of life. This means that a patient with HFrEF, ferritin of 80 µg/L, and a hemoglobin of 12.5 g/dL - technically not anemic by WHO criteria - should still be considered for intravenous iron therapy and screened using the 2023 ESC criteria. Second, the cardiorenal dimension of anemia in HF warrants systematic renal function assessment in every HF patient presenting with low hemoglobin. In the Fergana Valley, hypertension-related chronic kidney disease is prevalent, and its contribution to anemia via EPO insufficiency and hepcidin upregulation adds a further pathological layer that oral iron therapy alone cannot address. Collaboration between cardiologists, nephrologists, and hematologists - through a structured multidisciplinary approach - is essential for optimal management of these complex patients. Third, prevention must be integrated into primary care. Patients with established cardiovascular risk factors - hypertension, diabetes, obesity - who have not yet developed HF should receive annual hemoglobin and ferritin screening. Strengthening epidemiological monitoring and implementing region-specific prevention programs targeting modifiable risk factors are imperative for reducing cardiovascular disease morbidity and mortality in Central Asia. Nutritional counseling, early iron supplementation in at-risk populations, and optimization of dietary iron intake represent preventive measures that are entirely achievable within the existing primary care infrastructure of the Fergana Valley. The forthcoming availability of newer iron formulations such as ferric derisomaltose, which allows high-dose administration in a single infusion, may further simplify outpatient management and reduce the logistical barriers currently limiting intravenous iron access in regional centers.

Anemia in the setting of heart failure represents a multifactorial, bidirectionally reinforcing pathological state driven by hepcidin-mediated iron sequestration, erythropoietin insufficiency, chronic neurohormonal activation, and cardiorenal crosstalk. In the Fergana Valley, the rising cardiovascular disease burden combined with incomplete implementation of modern diagnostic and therapeutic protocols creates a critical gap between available evidence and actual clinical practice. Intravenous iron therapy - particularly ferric carboxymaltose - is the most evidence-based and clinically impactful intervention currently available for iron-deficient heart failure patients, regardless of whether frank anemia is present. Bridging the diagnostic gap by routinely measuring both ferritin and transferrin saturation, and ensuring reliable regional access to intravenous iron formulations, are the two most achievable steps toward meaningfully improving outcomes for this patient population in Uzbekistan's Fergana Valley.

References

1. Abdullayev, A. S. (2025). COMPARISON OF AGE-RELATED CHARACTERISTICS OF CEPHALOMETRIC INDICATORS: FRONTAL CHORD (N–B) AND PARIETAL CHORD (B–L) IN ARTIFICIALLY DEFORMED AND NORMAL SKULLS. World of Medicine and Biology, 21(93), 147-151.
2. Davlatovich, A. D., & Mishra, S. (2025). THE PATHOGENETIC SIGNIFICANCE OF SKIN BARRIER DYSFUNCTION IN ATOPIC DERMATITIS. GLOBAL TRENDS IN SCIENCE AND INNOVATION, 2(1), 233-239.
3. Ашуров, Д. Д. (2025). ИНВАЗИВНЫЕ МЕТОДЫ ЛЕЧЕНИЯ ВИТИЛИГО. In International Conference on Modern Science and Scientific Studies (pp. 304-307).

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

4. Davlatovich, A. D. (2025). CLASSIFICATION OF TATTOOS AND TATTOO REMOVAL. Web of Medicine: Journal of Medicine. Practice and Nursing, 3(2), 431-434.
5. Kamoldinovich, X. D. (2024). Intravenous Adnimnstration of Contrast Agents and Its Characteristics. Miasto Przyszłości, 48, 119-31.
6. Xojiraxmatov, D. K. (2023). THE IMPORTANCE OF COMPUTED TOMOGRAPHY IN THE DIAGNOSIS OF URETEROLITHIASIS AND ITS COMPLICATIONS. Procedia of Engineering and Medical Sciences, 7(12), 31-34.
7. Makhmudov, N. I., Dekhkanov, K. M., Botiraliev, A. B., Mirzamatov, N. I., & Khozhirahmatov, D. K. (2023). Results the use of minimally invasive surgical methods for the treatment of patients with polytrauma in the Fergana branch of the Rncemp. In BIO Web of Conferences (Vol. 65, p. 05035). EDP Sciences.
8. Маматханова, Г. (2021). Оптимизация медицинской учетной документации и внедрение электронных систем в здравоохранение. Общество и инновации, 2(8/S), 61-67.
9. Исмаилов, С. И., & Маматханова, Г. М. (2022). Электронный документооборот как важнейший фактор повышения эффективности управления здравоохранением. Eurasian journal of medical and natural sciences, 2(8), 38-45.
10. Mamatxanova, G. M., & Ismailov, S. I. (2021). Optimization of medical records and implementation of electronic systems in healthcare. The American Journal of Medical Sciences and Pharmaceutical Research, 3(01), 193-198.
11. Маматханова, Г. М., & Ашурова, М. Д. (2020). КОМПЛЕКСНАЯ ОЦЕНКА ДЕЙСТВУЮЩЕЙ ЭЛЕКТРОННОЙ БАЗЫ ПЕРВИЧНЫХ УЧЕТНО-ОТЧЕТНЫХ МЕДИЦИНСКИХ ДОКУМЕНТАЦИЙ В УЧРЕЖДЕНИЯХ ПЕРВИЧНОГО ЗВЕНА ЗДРАВООХРАНЕНИЯ. Экономика и социум, (2 (69)), 506-512.
12. Маматханова, Г. М., & Шерматова, Г. Т. (2021). Оптимизация медицинской учетной документации и автоматизация отчетностей.
13. Abduvaliyeva, F. T., Azizova, F. L., Akromov, D. A., & Sherkuziyeva, G. F. (2022). APPROVAL AND ECOLOGICAL-HYGIENIC ASPECTS OF WATER SUPPLY TO POPULATION POINTS.
14. Azizova, F. A. F. (2022). The role of local water sources in the centralized supply of drinking water to the population. British medical, 2(4), 175-180.
15. Ахмадалиев, Р. У., Турдиев, Ш. М., Абдувалиева, Ф. Т., & Саидова, С. А. (2020). ГИГИЕНИЧЕСКАЯ ОЦЕНКА УСЛОВИЙ ТРУДА И ОХРАНЫ ОКРУЖАЮЩЕЙ СРЕДЫ НА СТЕКЛОИЗГОТОВИТЕЛЬНЫХ ПРЕДПРИЯТИЯХ. Новый день в медицине, (4), 151-154.
16. Azizova, F. L., & Abduvaliyeva, F. T. (2021). Ecological and hygienic aspects of optimization of water supply of the population. The American journal of medical sciences and pharmaceutical research, 3, 48-53.
17. Pattoyevich, G. A. (2025). IRON DEFICIENCY ANEMIA IN CHILDREN: EARLY DIAGNOSIS AND MODERN TREATMENT APPROACHES. Web of Medicine: Journal of Medicine. Practice and Nursing, 3(5), 494-501.
18. Pattoyevich, G. A., & Nilufar, M. (2026). IMMUNOMORPHOLOGICAL CHARACTERISTICS OF PERIPHERAL BLOOD IN CHILDREN WITH CONGENITAL

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

IMMUNODEFICIENCY. FRONTIERS OF KNOWLEDGE AND INTERDISCIPLINARY DISCOVERY, 2(1), 90-96.
19. Pattoyevich, G. A. (2025). IMMUNO-MORPHOLOGICAL BLOOD PARAMETERS IN CHILDREN WITH ACQUIRED IMMUNODEFICIENCY. GLOBAL TRENDS IN SCIENCE AND INNOVATION, 2(1), 255-261.
20. Asqarov, I., & Abdujabborova, C. (2025). ANALYSIS OF THE BIOLOGICAL ACTIVITY OF THE FOOD ADDITIVE" AS LUPINUS". Scientific journal of the Fergana State University, (2), 195-195.
21. Абдужабборова, Ч. С. (2024). ИСПОЛЬЗОВАНИЕ ЛЮПИНА В НАРОДНОЙ МЕДИЦИНЕ И РЕЦЕПТАХ.“Fizikaviy va kolloid kimyo fanlarining fundamental va amaliy muammolari hamda ularning innovatsion yechimlari” Xalqaro ilmiy-amaliy anjuman.
22. ABDUJABBOROVA, C. (2024). O'TKIR ZAHARLILIGINI ANIQLASH" LUPINUS AS. UNIVERSAL Учредители: Ilm Fan Fidoiylari Mchj, 1(9), 151-157.
23. Mamatqulova, S. A., & Abdujabborova, C. S. qizi.(2024). LYUPIN O‘SIMLIGI KIMYOVIY TARKIBI VA XALK TABOBATIDA QO‘LLANILISHI. Educational research in universal sciences, 3(3), 73-79.
24. Mukhtarjanovna, I. G. (2023). Developing the Principles of Studying and Treatment of Vaginal Dysbiosis During Pregnancy. Texas Journal of Medical Science, 16, 67-68.
25. Mukhtarzhanovna, I. G. (2024). Development of Principles of Study and Treatment of Vaginal Dysbiosis During Pregnancy. In International Congress on Biological, Physical And Chemical Studies (ITALY) (pp. 112-115).
26. G’aniyevna, J. B. (2025). OREGANO-AS. In OZIQ-OVQAT QO’SHILMASI TARKIBIDAGI FARMAKO-TOKSIKOLOGIK XUSUSIYATLARINI ORGANISH. In International Educators Conference (pp. 208-214).
27. Jumanova, B. (2023). CHEMICAL COMPOSITION OF THE MARMARAK MEDICINAL PLANT (SALVIA OFFICINALIS) AND USE IN PEOPLE'S MEDICINE. B ACADEMIC RESEARCH IN MODERN SCIENCE (Т. 2, Выпуск 26, сс. 158–162). Zenodo.
28. Jumanova, B. G. (2025). CLINICAL EFFECTIVENESS OF THE DIETARY SUPPLEMENT OREGANO AS IN INFLAMMATORY DISEASES OF THE ORAL CAVITY. Advances in Science and Environment, 1(12), 12-14.
29. Sattievna, D. G. (2024). FARG’ONA VILOYATIDA REPRODUKTIV YOSHDAGI AYOLLARNI KONTRASEPTIV VOSITALARNI QO’LLASH USULLARI HAQIDAGI XABARDORLIK DARAJASINI O’RGANISH. Лучшие интеллектуальные исследования, 14(2), 239-243.
30. Йулдошева, Д. С., Ёкубов, Ф. Ф., & Рахматов, С. А. (2024). СОВРЕМЕННЫЕ КЛИНИКО-ЭПИДЕМИОЛОГИЧЕСКИЕ ОСОБЕННОСТИ МИКРОСПОРИИ И ТРИХОФИТИИ. IMRAS, 7(1), 689-693.
31. Kumar, S. (2025). PATHOPHYSIOLOGICAL BASIS OF AUTOIMMUNE PROCESSES IN VITILIGO. GLOBAL TRENDS IN SCIENCE AND INNOVATION, 2(1), 315-322.
32. Sobirjonova, G. (2022). FORECASTING OF AGRICULTURAL PRODUCTS INCLUDED IN THE CONSUMER BASKET. Science and innovation, 1(A7), 839-841.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

33. Shakhzodakhon, S. (2025). OCCUPATIONAL ALLERGIES: RISK FACTORS, DIAGNOSIS, AND DEVELOPMENT OF PREVENTIVE MEASURES. In Scientific Conference on Multidisciplinary Studies (pp. 275-281).

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5